Research Papers:

Bromodomain protein 4 is a novel predictor of survival for gastric carcinoma

Yixin Zhu, Weijin Yang, Guangnian Ji, Nan Lin, Weihang Wu, Ping Xiong, Chenxin Zheng, Lei Yan, Peng Wan and Yu Wang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:31092-31100. https://doi.org/10.18632/oncotarget.16087

Metrics: PDF 1452 views  |   HTML 1988 views  |   ?  


Yixin Zhu1,*, Weijin Yang2,3,*, Guangnian Ji4,*, Nan Lin2,3, Weihang Wu2,3, Ping Xiong1, Chenxin Zheng1, Lei Yan1, Peng Wan2,3, Yu Wang2,3

1Clinical Institute of Fuzhou General Hospital, Fujian Medical University, Fuzhou, Fujian 350025, China

2Department of General Surgery, Dongfang Hospital, Xiamen University, Fuzhou, Fujian 350025, China

3Department of General Surgery, Fuzhou General Hospital, Fuzhou 350025, China

4Dongfang Hospital Affiliated to Xiamen University, Xiamen University, Xiamen, Fujian 361005, China

*These authors contributed equally to this work as co-first authors

Correspondence to:

Yu Wang, email: [email protected]

Keywords: BRD4, gastric adenocarcinoma, surgical resection, predictor, prognosis

Received: July 20, 2016     Accepted: March 01, 2017     Published: March 10, 2017


Expression of bromodomain protein 4 (BRD4) has been reported to predict a worse prognosis in solid tumors. However, its expression profile and prognostic value in gastric carcinoma (GC) remains unknown. Here we investigated BRD4 expression in GC and explored its association with patient survival. Tissue samples were obtained from 95 GC patients who underwent surgical resection to remove the primary tumor from January 2009 to December 2010. Immunohistochemistry was used to detect the expression of BRD4 in GC tissues and adjacent normal tissues. Kaplan–Meier survival curves and Cox proportional hazards regression were used to analyze the data of BRD4 expression profile and clinicopathological characteristics. Immunohistochemical analysis revealed BRD4 was overexpressed in GC tissue compared with adjacent normal tissue. BRD4 expression was significantly associated with TNM stage (p < 0.001), lymphatic permeation (p = 0.011), and vital status at the end of follow-up (p < 0.001). Kaplan–Meier survival curves and the log-rank test demonstrated that higher BRD4 expression was an adverse predictive factor for survival in GC. Multivariate analysis by Cox proportional hazards regression revealed that BRD4 expression was an independent worse prognostic factor in GC. In conclusion, BRD4 could act as a potential biomarker for prognostic assessment of GC.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16087